PARAMUS, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an agreement with a leading provider of global clinical trial technologies and services, Numoda Corporation.
